Potential of Human Umbilical Cord Matrix and

Rabbit Bone Marrow–Derived Mesenchymal Stem

Cells in Repair of Surgically Incised Rabbit External

Anal Sphincter by Aghaee-afshar, Mahmoud et al.
ORIGINAL CONTRIBUTION
Potential of Human Umbilical CordMatrix and
Rabbit BoneMarrow–DerivedMesenchymal Stem
Cells in Repair of Surgically Incised Rabbit External
Anal Sphincter
Mahmoud Aghaee-afshar, M.D.1 • Mohammad Rezazadehkermani, M.D.2
Alireza Asadi, M.D.3 • Reza Malekpour-afshar, M.D.4 • Armita Shahesmaeili, M.D.6
Seyed Noureddin Nematollahi-mahani, Ph.D.5,6,7
1 Department of Surgery, Afzalipour Hospital, Kerman University of Medical Sciences, Kerman, Iran
2 Kerman Medical Students Research Center, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman,
Iran
3 Kerman Neuroscience Research Center, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman,
Iran
4 Department of Pathology, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
5 Department of Anatomy, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
6 Kerman Physiology Research Center, Kerman University of Medical Sciences, Kerman, Iran
7 Afzal Research Institute (NGO), Kerman, Iran
PURPOSE: Anal sphincter defects and fecal incontinence
are complicated surgical problems. We investigated the
ability of human umbilical cord matrix (hUCM) and
rabbit bone marrow (rBM) stem cells to improve anal
sphincter incontinence due to induced sphincter defects
without surgical repair.
METHODS: We harvested hUCM cells from human
Wharton’s jelly and rBM stem cells from rabbit femurs
and tibias. To induce sphincter defects, we made an
incision in the external anal sphincter. Rabbits were
randomly allocated to 5 groups to receive either no
intervention (n 3) or injections of 104 hUCM cells in
medium (10 L RPMI-1640), rBM cells in medium,
medium only, or normal saline (n 7 per group), 2
weeks after sphincterotomy. Transplanted cells were
tracked in the injured sphincters by prelabeling with
bromodeoxyuridine. Electromyography was performed
before and 2 weeks after the external anal
sphincterotomy, and 2 weeks after cell transplantation.
We also evaluated the proliferation and differentiation of
injected cells with histopathologic techniques.
RESULTS: Electromyography showed significant
improvement in sphincter function 2 weeks after local
injection of rBM stem cells compared with pretreatment
values and controls. Moderate, nonsignificant
improvement was observed with hUCM cell injection.
Cells with incorporated bromodeoxyuridine were
detected at the site of injury after transplantation of
hUCM and rBM. Histopathologic evaluation showed
normal or muscle-dominant sphincter structure in all
animals receiving rBM and fibrous-dominant sphincter
structure in most animals receiving hUCM.
CONCLUSIONS: Stem cell injection at the site of injury
can enhance contractile function of the anal sphincter
without surgical repair. Transplantation of stem cells,
particularly bone marrow mesenchymal cells, may
provide an effective tool for treating anal sphincter
injuries in humans.
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F
ecal incontinence, which can range from a daily loss
of all stools to occasional soiling, is a gastrointestinal
problem that significantly impairs quality of life.1 Al-
though estimates of prevalence rates vary, a recent consen-
sus statement estimated the rate of fecal incontinence in
noninstitutionalized persons at 6% in women younger
than 40 years, 15% in women older than 40, and 6 to 10%
inmen.2 Aging is amajor risk factor for fecal incontinence,
and older people living in residential homes are particu-
larly affected, with at least twice-monthly episodes re-
ported in more than 16% of residents and at least weekly
episodes in 10%.3 It is not known whether aging directly
affects sphincter function or aggravates the effect of an anal
sphincter tear, but in long-term studies inwomen, only 6%
of cases were due to an anal sphincter tear.4 In most pa-
tients, the cause of incontinence is likely to be a cumula-
tive,multifactorial process.5 Nonsurgical options for treat-
ment include medications to slow transit or increase stool
consistency, special diets, habit training, and biofeedback
with sphincter exercise, but these approaches appear to
achieve complete continence in no more than approxi-
mately 50 to 60% of patients.6 Surgical options for correc-
tion of fecal incontinence, which include procedures such
as direct sphincter repair, artificial sphincter implanta-
tion, and colostomy diversion, also achieve varying rates of
success.7
The most recent suggested procedure for treatment of
fecal incontinence is regenerative medicine. The ability of
bone marrow (BM) stem cells to form muscle in vitro and
in vivo has been previously demonstrated,8 and BM cells
have been used as a source of cell therapy in animal mod-
els.9–12 Umbilical cord matrix (UCM) cells are embryonic
derivatives ofWharton’s jelly which are easily acquired and
propagated in cell culture laboratories. These cells have
been recently introduced as a promising source of stem
cells, and their capacity to differentiate into chondrocyte,
neurons, glia, and cardiac muscle has been demonstrated
in some species.12–15 A recent study in rats showed the
ability of a combination of surgical repair and injection of
bone marrow stem cells to correct fecal incontinence.9
The present study was designed to find out whether
stem cell therapy may improve anal sphincter inconti-
nence without surgical repair. We evaluated the potential
of rabbit bone marrow (rBM) and human umbilical cord
matrix (hUCM) stem cells in repair of fecal incontinence
resulting from surgical division of the rabbit external anal
sphincter (EAS sphincterotomy).
MATERIALS ANDMETHODS
This study was performed in accordance with the guide-
lines for the care and use of laboratory animals established
by the local ethics committee at Kerman University of
Medical Sciences, Kerman, Iran.
Animals
Thirty-five male white New Zealand rabbits (weight range
2.5–3.5 kg) provided fromRazi Institute (Karaj, Iran) were
assigned to the experiments. Four of these were used for
bone marrow stem cell collection. The remaining animals
were kept in an animal room with a 12-hour-day/night
cycle and free access to water and chewing rodent food.
Experimental Design
All animals used for the comparative study underwent
clinical evaluation for anal sphincter performance andEAS
sphincterotomy. Animals were randomly allocated to 5
groups to receive the following treatment: 1) viable hUCM
cells in medium; 2) viable rBM cells in medium; 3) me-
dium only; 4) normal saline; or 5) no intervention. All
study preparations were injected at the site of injury.
Groups 1 through 4 contained 7 animals each, and the
treatment-free control group contained 3 animals.
In all groups, clinical examination and electromyogra-
phy (EMG) were performed before the sphincterotomy,
2 weeks after the sphincterotomy but before stem cell
injection, and 2 weeks after stem cell injection. After the
final EMG, animals were killed and the EAS was re-
moved for immunohistochemical and histopathologic
evaluations.
Chemicals
All chemicals were purchased from Sigma-Aldrich Chem-
ical Company (St. Louis, MO) unless otherwise stated.
rBMCell Culture
rBM cells were collected after the rabbit femur and tibia
marrow cavity were extensively flushed out with heparin-
ized Hank’s balanced salt solution (HBSS). After aseptic
marrowdraining, the collected suspensionwas centrifuged
over 50% Pure-Sperm (Nidacon, Go¨teborg, Sweden; a
density gradient solution used for sperm preparation in
assisted reproductive technology procedures) in HBSS at
350 g for 20 minutes. The supernatant fraction was col-
lected aseptically and centrifuged at 500 g for 10minutes
after washing with HBSS. Pelleted cells were cultured in
25-cm2 Falcon cell culture flasks (Becton Dickinson and
Company, Franklin Lakes, NJ) in RPMI-1640 supple-
mented with 20% fetal bovine serum (FBS; Gibco, Grand
Island, NY), 100 IU/ml penicillin, and 60 g/ml strepto-
mycin. Flasks were incubated at 37°C in a humidified at-
mosphere containing 5% CO2 in the air. After overnight
incubation, the floating cells were discarded and the at-
tached cells were harvested in the same medium. Once the
adherent fractions had reached80% confluence, the cells
were trypsinized with 0.5 g/l trypsin and 0.2 g/l EDTA in
phosphate buffered saline (PBS) for cell transplantation or
cryopreserved in liquid nitrogen for further use.
1754 AGHAEE-AFSHAR ET AL: STEM CELLS FOR ANAL SPHINCTER REPAIR
hUCMCell Culture
The procedures for collecting human umbilical cords were
approved by the local ethics committee at KermanUniver-
sity of Medical Sciences, Kerman, Iran. Human umbilical
cords were collected aseptically from cesarean section nor-
mal live births after written informed consent was ob-
tained from the mother. Umbilical cords were transferred
in HBSS with 100 IU penicillin G, 60 g/ml streptomycin,
and 50 g/ml amphotericin B to the laboratory equipped
with cell culture facilities. In the cell laboratory, the umbil-
ical cords were carefully dissected free of the amniotic
membrane and the cord vessels with fine forceps and a pair
of scissors. The Wharton’s jelly was washed several times
with PBS, minced into small (5- to 6-mm) pieces, and put
in 3-cm Petri dishes; then 1mLDulbecco’s modified Eagle
medium F-12 (DMEM/F12) supplemented with 20% FBS,
100 IU/ml penicillin, and 60 g/ml streptomycin was
added slowly to each plate. Plates were kept in a 37°C hu-
midified incubator with 5%CO2 in the air. After 24 hours,
2 mL of the same medium was added to each Petri dish.
The explants were detached from the plates and discarded
after 5 to 6 days of cultivation. When the propagated cells
reached confluence of 80 to 90%, the cells were passaged
after treatmentwith 0.5 g/l trypsin and 0.2 g/l EDTA in PBS
and subcultured under the previous condition. Cells at ear-
lier passages (2–6) were used for further experiments.
Labeling of Transplanted Cells
For tracking the transplanted cells in the injured sphinc-
ters, the cells were prelabeled with bromodeoxyuridine
(BrdU; Chemicon-Millipore, Temecula, CA) before the
transplantation was carried out.16 Briefly, each type of
stem cell (rBM and hUCM) was incubated with 10 M of
BrdU in the culture medium for 48 hours in a humidified
37°C incubator with 5% CO2 in the air. The efficacy of
BrdU incorporation was assessed in a pilot study by stain-
ing with a BrdU detection kit that used a biotinylated
monoclonal antibody to BrdU (BrdU Immunohistochem-
istry Kit, Chemicon-Millipore).
Surgical Procedures and Injection of Study Preparations
Rabbits were anesthetized with 80 mg/kg ketamine and 12
mg/kg xylazine, and then fixed in the lithotomy position.
In each animal, a sphincterotomy was performed in the
right lateral portion of the EAS.
Two weeks after the EAS sphincterotomy, either a
stem cell or a control preparation was injected at the site of
the EAS sphincterotomy scar with a 27-gauge needle at-
tached to a Hamilton syringe. The treatments received by
each group are summarized in Table 1. The stem cell
groups received 104 cells of either hUCM or rBM sus-
pended in 10 L of RPMI-1640. Control animals in the
medium group received 10L of RPMI-1640, and those in
the saline group received 10 L of PBS. To suppress the
probable immune response to the stem cell preparations,
rabbits in the hUCM and rBM groups received an intra-
muscular injection of 10 mg/kg cyclosporine A (Novartis,
Ta¨by, Sweden) once per day, for 2 weeks.
Clinical Evaluation
Clinical examination of all animals was performed before
the sphincterotomy, 2 weeks after sphincterotomy (just
before injection of the study preparation), and 2 weeks
after administration of the study preparation. Any sign of
incontinence was noted, including flaccid atonic sphincter
and open anal orifice with loose fecal consistency.
Electromyography of the Sphincter
Electromyography was carried out before the sphincterot-
omy (pre–EAS division), 2 weeks after sphincterotomy
just before injection of the study preparation (post–EAS
division), and 2 weeks after administration of the study
preparation (posttreatment). The Medelec-Synergy EMG
monitoring system (Cardinal Health NeuroCare, Madi-
son, WI) and the Oxford recording program designed for
this device were used. The procedure was carried out for all
animals in each group as follows: After shaving the thigh
and establishing a ground connection, we inserted a Med-
elec ELITE disposable concentric 26-gauge needle elec-
trode (Cardinal Health), which had a 0.46-mm diameter,
25-mm length, and 0.07-mm2 recording area, at the 9
o’clock position of the anal canal. The needle was inserted
through the perianal skin adjacent to the mucocutaneous
junction; the tip of the electrode entered perpendicular to
the skin close to the anal orifice (0.2 cm from the anal ring).
The device was set at a 5- to 10-millisecond/cm sweep
TABLE 1. Summary of treatments received by each study group
Study group N EAS sphincterotomy hUCM (104 cells) rBM (104 cells) Culturemedium Cyclosporin A PBS
hUCM 7      
rBM 7      
Medium 7      
Saline 7      
No treatment 3      
EAS external anal sphincter; hUCM human umbilical cord matrix; PBS phosphate buffered saline; rBM rabbit bone marrow; treatment administered; treat-
ment not administered.
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speed and 100 to 200 V of gain; motor units per 20 sec-
onds were recorded during anal functional sphincter activ-
ity (contraction).
Immunohistochemistry and Histopathology
Two weeks after administration of the study preparations
(after the final EMG recording), animals were killed by
intracardiac injection of 10% potassium chloride in dis-
tilled water. The EAS was excised carefully, and the site of
the EAS sphincterotomy (the site where the cells were in-
jected) was marked using a simple suture. The specimens
were fixed in 10% formaldehyde in PBS for 24 hours. Tis-
sues were prepared with routine histologic procedures and
5-mthick sections were arranged and stainedwith hema-
toxylin and eosin.
Identification of Engrafted Cells. Five-m thick slices
were deparaffinized and rehydrated, and the DNA was de-
naturized using 2N HCl for 30 minutes at room tempera-
ture. Samples were rinsed in PBS, incubated for 30minutes
at 37°C with trypsin, washed with PBS, and incubated for
10minutes in 5% hydrogen peroxide to block endogenous
peroxidase activity. Samples were then washed with tris
buffer (pH  7), and monoclonal anti-BrdU (BrdU Im-
munohistochemistry Kit, Chemicon-Millipore) was ap-
plied to each slide for 45 minutes in a humidified environ-
ment at 37°C. Slides were washed 2 times with tris buffer,
and goat anti-mouse IgG labeled with peroxidase was
added to each slide and incubated at 37°C for 30 minutes.
After the slides were washed with PBS, diaminobenzidine
(DAB)was added to each slide and incubated at room tem-
perature for 30 minutes. After being washed with distilled
water, the slides were counterstained with hematoxylin
and prepared for microscopic observation. Slides were
carefully evaluated with a light microscope equipped with
a digital camera (Olympus, Japan).
Evaluation of Tissue Structure. The prepared slides were
carefully reviewed by a pathologist who was blind to the
arrangements of intervention. The pathologist evaluated
the presence of newly formed striatedmuscles at the site of
cell transplantation and reported the results in 3 categories
as follows: 1) normal structural sphincter in which hyper-
trophied regular sphincter muscle was observed; 2) mus-
cle-dominant sphincter containing a mixture of muscle
and fibrous tissue, with muscular structures predominant;
and 3) fibrous tissue–dominant sphincter inwhich fibrous
structures were predominant (Fig. 1).
Statistical Analysis
Data from EMG recordings are presented as mean stan-
dard error of the mean (SEM) for each group. The efficacy
of EAS sphincterotomy was tested by comparing pre–EAS
division and post–EAS division EMG data within groups
by use of a paired-sample t test or a nonparametric equiv-
alent test, depending on whether normality could be as-
sumed. Post–stem cell injectionEMGdata andhistopatho-
logic results in different groups were analyzed by use of the
FIGURE 1. Histologic classification of sphincters after cell transplantation. A. Normal sphincter with normal muscle fibers (black arrow) and
some vessels (white arrow). B. Muscle-dominant sphincter (example from rBM group). Black arrows showmature muscle fibers, white arrows
showmaturing muscle fibers, and arrow heads show active mesenchymal cells. C. Fibrous-tissue–dominant sphincter. Asterisks show areas of
connective tissue; arrows show normal or degenerating muscle fibers. Original magnification in A and B,200; in C,100.
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Kruskal-Wallis test followed by the Mann-Whitney U test
for evaluation of significance of differences between
groups. Data analysis was performed using SPSS for Win-
dows software, Version 11.5 (SPSS, Chicago, IL). P values
0.05 were considered significant.
RESULTS
In this study, 25 rabbits withstood the surgical and treat-
ment procedures; 6 rabbits died, 2 in each stem cell group,
one in the medium group, and one in the saline group.
Results of Clinical Examination
No sign of fecal incontinence was detected in any of the
animals before surgical intervention. Two weeks after EAS
sphincterotomy all the excised animals had a flaccid
sphincter with an open anal orifice, and most had loose
fecal consistency. Two weeks after cell transplantation (at
the time of the EMG recording), the EAS was judged to be
competent in 4 animals in the rBM group and in 2 animals
in the hUCM group, and moderately functional in 2 ani-
mals in the group that received medium alone.
Results of Electromyography
Pre–EAS division EMG data were analyzed to ascertain
whether differences existed among groups that would
indicate problems with randomization. No significant dif-
ference among treatment groups was detected (Table 2).
As shown in Figure 2, electromyography 2 weeks after
EAS sphincterotomy (just before administration of the
study preparations) demonstrated a significant overall de-
crease in mean spikes per second compared with pre–EAS
division values (P 0.001), indicating that the sphincter-
otomy was successful. No significant differences were
observed among groups after EAS sphincterotomy (post–
EAS division) (Table 2).
As also shown in Table 2, the mean number of spikes
per second increased significantly after administration of
rBM (P  0.01). In addition, posttreatment EMG values
were significantly higher in the rBM group than in the 3
control groups. In the hUCM group, the number of spikes
per second increased after treatment, but not significantly,
and posttreatment differences between the hUCM group
and control groupswere not significant. No significant im-
provement in EMG values was observed after local injec-
tion of medium or normal saline at the site of injury. EMG
traces from a normal rabbit sphincter and representative
examples of the study treatments are shown in Figure 3.
Immunohistochemistry
On slides stained with the BrdU detection kit, the nuclei of
cells with incorporated BrdUwere colored brown, whereas
other cells had a bluish hematoxylin nuclear stain (Fig.
4A). The efficacy of BrdU incorporation was estimated in
the pilot study to be approximately 50 to 60%.
BrdU-positive cells were detected at the site of injec-
tion both in animals receiving rBM (Fig. 4B) and in those
receiving hUCM (Fig. 4C).
Histopathologic Evaluation of Sphincter Structure
Results of the histopathologic evaluation of sphincter
structure are shown in Table 3. All animals that received
rBM cells had normal or muscle-dominant sphincter
structure, whereas most animals that received hUCM had
fibrous-dominant sphincter structure. The difference be-
tween groups was not statistically significant (P  0.26).
However, the difference between the results of the rBM
group and the normal saline group was nearly significant
(P 0.054).
DISCUSSION
The present study investigated the efficacy of transplanta-
tion of 2 types of stem cells in repairing complete EAS
FIGURE 2. Results of electromyography (EMG) before and 2 weeks
after sphincterotomy of the external anal sphincter (EAS), showing a
significant decrease in mean spikes/second ( standard error of the
mean) (P 0.001).
TABLE 2. Results of electromyography before and after
sphincterotomy and after treatment with stem cells or a control
preparation
Study group n
Pre–EAS
division
Post–EAS
division Posttreatment
hUCM 5 37.25 6.57 0.06 0.60 11.25 7.16
rBM 5 24.64 2.79 0.54 0.54a 13.59 2.97b
Medium 6 35.28 3.87 0.25 0.25 4.75 3.04c
Normal saline 6 33.33 2.47 0.40 0.40 1.10 1.10d
No treatment 3 21.33 7.72 0 0e
rBM rabbit bone marrow; EAS external anal sphincter; hUCM human umbili-
cal cord matrix. • Data are mean spikes/second standard error of the mean be-
fore EAS sphincterotomy (pre–EAS division), 2 weeks after EAS sphincterotomy
(post–EAS division), and 2 weeks after injection of study preparation (posttreat-
ment). • Each group is labeled with a superscript digit denoting significant be-
tween-group comparisons as follows: a vs. b, P 0.01; b vs. c, P 0.05; b vs. d, P
0.01; and b vs. e, P0.001.
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defects in rabbits without surgical intervention. rBM cell
transplantation significantly improved defects in sphincter
anatomy and physiology caused by sphincterotomy. A re-
cent study has demonstrated the efficacy of a combination
of primary surgical repair and bone marrow stem cell in-
jection for treatment of surgically injured anal sphincters
in rats.9However, to our knowledge, stem cell injection has
not previously been used to treat anal sphincter injuries
without surgical repair. In previous studies, injection of
both autologousmyoblasts and fibroblasts has been shown
to have a positive effect on urinary incontinence in wom-
en.17 Similar results in human male urethral sphincter de-
fects following prostatectomy were reported by the same
group after they used a combination of myoblasts and fi-
broblasts.18
In our study, electromyographic recordings showed a
significant improvement in sphincter muscle function in
rabbits that received rBM cells, and a nonsignificant, rela-
tive improvement in rabbits that received hUCMcells. Our
clinical observations confirmed this finding, as we ob-
served competent sphincters in animals that showed im-
provement in EMG values after receiving stem cells, and
atonic nonfunctional sphincters in those whose EMG val-
ues did not improve after intervention.
Four of the 5 rabbits in the rBM group had higher
EMG values than any of the control rabbits receiving cul-
ture medium, and the sphincter of only one rabbit treated
with rBM was flaccid after cell therapy. Greater variation
was found in the hUCM group: Although fewer animals in
this group had improved anal sphincter tone after treat-
ment, 2 of the 5 showed greater improvement in results of
EMG than any animals that received rBM (data not
shown). We do not have a definitive explanation for such
uneven results. Problems in cell preparation, the technique
of cell transplantation, or to a lesser extent the EMG re-
cording may be the source of the variation.
The plasticity of muscular tissue following injury has
recently been demonstrated.10 In our study, detection of
the nuclear cell marker BrdU in cells at the site of injury, as
well as our histopathologic findings of newmuscle fibers in
the cell-transplanted area (Fig. 4B) after local injection of
stem cells, suggest that transplanted stem cells did indeed
contribute to the formation of new muscular tissue at the
site of injury.However, we did not usemyogenic cellmark-
ers in conjunction with anti-BrdU staining to confirm the
origin of such newly formed muscle fibers. The exact con-
tribution and differentiation of transplanted stem cells
intomuscular tissue should be explored by double labeling
FIGURE 3. Electromyography traces in various groups. EMG traces from no treatment, normal saline and medium were nearly identical;
therefore, a trace frommedium group is presented.
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of engrafted cells with a cell proliferation marker and a
specific myocyte marker.
Bonemarrow stem cells may differentiate into various
cell types, including chondrocytes, osteocytes, neuron-like
cells, and myocytes, in vitro as well as in vivo.8 The milieu
after transplantation appears to have an effect on differen-
tiation of transplanted cells; for example, when human
bone marrow–derived mesenchymal stem cells are trans-
planted into a damaged heart, myogenic factors such as
TNF, IL6, and CRP produced from host cardiomyocytes
may influence the differentiation of the transplanted cells
into mature contracting cardiomyocites.19–22 Although
our observation of active mesenchymal cells andmaturing
muscle fibers in cell transplanted areas (Fig. 1B) suggests
that a similar mechanism may be involved in sphincter
improvement following cell therapy, the precise mecha-
nism of differentiation of stem cells into muscle tissues
remains to be explored.
hUCM and rBM cells are known to secrete many
growth factors which contribute to cell propagation and
differentiation (refer to Powell et al. 199923 for a review).
hUCM cells have been described as having the characteris-
tics of myofibroblasts,12 which play a role in healing by
producing a wide range of cytokines, growth factors, che-
mokines, and inflammatory mediators and can produce
both insulin-like growth factors (IGF) I and II. IGF-I has
been shown to be a powerful mitogenic factor for myocyte
cells and has been previously suggested for the treatment of
progressive muscular dystrophy.24 Some authors have dis-
cussed paracrine effects of transplanted stem cells on host
tissue stem cells to proliferate and differentiate inside the
injured area.25,26 Although we could not define the exact
mechanism by which stem cells improved rabbit sphincter
activity in our study, either a direct contribution of trans-
planted stem cells to repair of the injured area,15,16 host
stem cell mobilization and activation in response to para-
crine factors secreted by transplanted cells,25,26 or a com-
bination of thesemechanismsmay have contributed to our
results.
Umbilical cord matrix cells originate early in embryo-
genesis (aroundday 12 of gestation) fromextra-embryonic
FIGURE 4. A. The nucleus of a cell with incorporated BrdU is colored dark brown (black arrow), and the nucleus of a cell without incorporated
BrdU is colored pale blue (white arrow). B and C show cells with incorporated BrdU (black arrows) between sphincter cells of rabbits treated
with hUCM (B) or rBM (C).
TABLE 3. Distribution of various sphincter structures found on
histopathologic examination 2 weeks after administration of
study preparations
Sphincter structure
Study group n Normal
Muscle-
dominant
Fibrous-
dominant
hUCM 4* 1 0 3
rBM 5 4 1 0
Medium 6 2 1 3
Saline 5* 1 2 2
No treatment 3 2 0 1
hUCM human umbilical cord matrix; rBM rabbit bone marrow.
*The results of one sample in the Saline group and one sample in the hUCM group
were excluded because of poor quality of the processed tissues.
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mesoderm.27 Due to their embryonic nature, UCM cells
may not induce immune responses or produce tumors in
the host.15 It has been shown that xenotransplantation of
porcine UCM cells into rat brain had not triggered an im-
mune response after 2 to 6 weeks of follow-up.28 This find-
ing was supported by data on transplantation of hUCM
cells into the brain of hemiparkinsonian rats.15 However,
we were not certain whether the hUCM cells used in our
studywould elicit an immune response in the host animals.
Therefore, we suppressed the immune system of recipient
rabbits in both experimental groups by daily injection of
cyclosporine A. Further studies should be conducted to
define the extent of antigenic properties of hUCM cells
with confidence. If their nonimmunogenic properties can
be confirmed, hUCM cells may potentially serve as a good
source of stem cells for repair of damaged tissues in hu-
mans.
Scar formation at the site of injury is a common phe-
nomenon leading to weakness of the sphincter and can be
a problem in clinical practice, because surgery to repair the
sphincter is often delayed. In the present study, we injected
stem cells at the site of injury 2 weeks after EAS sphincter-
otomy, at a time when fibrosis had previously occurred
and resulted in scar formation. Our data suggest that ad-
ministration of rBM cells, and to a lesser extent hUCM
cells, may aid repair of anal sphincter defects even after a
delayed injury.
The present study demonstrated promising effects of
transplanted nonembryonic stem cells for repair of anal
sphincter defects without surgical intervention in an ani-
mal model. One limitation of our study is that we did not
assess the effective contraction of the sphincter bymanom-
eter. Further studies should evaluate other aspects of trans-
planting such cells; for example, the optimal number of
stem cells, the exact method of injection, the most appro-
priate time of injection in the therapeutic procedure, the
advantages and disadvantages of autologous stem cell
transplantation, and the effects of combining cell trans-
plantation with administration of growth factors. A con-
trolled clinical trial will be needed to illuminate the long-
term efficacy and safety of stem cell therapy for treatment
of fecal incontinence in humans.
CONCLUSION
Our study suggests that bone marrow mesenchymal cells,
and to a lesser extent human umbilical cord matrix cells,
may be effective in treating anal sphincter injuries in fu-
ture clinical applications of stem cell therapy. Although
further studies are required to confirm and increase our
knowledge before this method can be used in the clinical
setting, such cells may be able to repair anal sphincter de-
fects and contribute to normalizing the physiology of in-
jured sphincters.
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